Latest Breaking News On - Binish chudgar - Page 1 : comparemela.com

FDA approves Hercessi as latest interchangeable Herceptin biosimilar

FDA approves Hercessi as latest interchangeable Herceptin biosimilar
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Binish chudgarMindy valcarcelChrys kokinoBymatthew shinkleAccord biopharma intas pharmaceuticalsIntas pharmaceuticalsAccord biopharma

Accord BioPharma get FDA OK for Herceptin biosimilar

Hercessi is used fora variety of cancer treatments.

United statesJason zhuBinish chudgarChrys kokinoDrug administration for hercessiEuropean commissionEuropean unionIntas pharmaceuticalsEuropean medicines agencyShanghai henlius biotechAccord biopharmaDrug administrationNational medical products administrationNorth america

Henlius Trastuzumab Receives FDA Approval in the United States | Taiwan News

Henlius Trastuzumab Receives FDA Approval in the United States | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSaudi arabiaBinish chudgarJason zhuChrys kokinoIntas pharmaceuticals ltdDrug administrationEuropean medicines agencyIntas pharmaceuticalsNational medical products administrationAccord biopharma incAmerican cancer societyHenlius biotech incEuropean commissionInternational agency for research on cancer

Herceptin Biosimilar, Hercessi, Approved by FDA in Breast, Gastric Cancers

The FDA has approved Hercessi for the adjuvant treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Jason zhuBinish chudgarEuropean unionEuropean commissionIntas pharmaceuticalsDrug administrationHenlius biotech incEuropean medicines agencyNational medical products administrationHenlius biotechAccord biopharmaBreast cancerMetastatic breast cancer

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

United statesChrys kokinoHenlius trastuzumabBinish chudgarJason zhuEuropean medicines agencyNational medical products administrationHenlius biotech incIntas pharmaceuticalsEuropean unionEuropean commissionHenlius biotechNorth americaAccord biopharmaTrastuzumab strfHer2 overexpressing breast cancer